The U.S. Food and Drug Administration (FDA) declined approval of retifanlimab-dlwr for patients with metastatic non-small cell lung cancer (NSCLC) in the United States because of manufacturing ...

Immutep Limited (NASDAQ:IMMP) shares plunged roughly 80% on Friday after the biotechnology company announced it would ...

The Commissioner’s National Priority Voucher pilot program enabled rolling review, enhanced FDA interaction, and a rapid 44-day decision, alongside breakthrough therapy and priority review ...

Sunvozertinib is the first targeted oral treatment for NSCLC with EGFR exon 20 insertion mutations, approved for post-chemotherapy progression cases. The WU-KONG1 Part B study showed a 53.3% objective ...

Racial disparities persist in receipt of curative treatment for early-stage non-small cell lung cancer (NSCLC), according to a study published online March 2 in JAMA Network Open. Olivia F. Lynch, MD, ...

Incyte is looking to expand the use of its PD-1 blocker Zynyz to treat non-small cell lung cancer. The FDA’s rejection did ...

Small cell lung cancer (SCLC) is a fast-growing cancer that forms in the lung. It's one of two types of lung cancer. The other type is non-small cell lung cancer (NSCLC). SCLC is less common than ...

Brachytherapy, a form of internal radiotherapy, has emerged as a promising treatment modality for patients with non-small cell lung cancer (NSCLC). This technique involves the precise implantation of ...

Please provide your email address to receive an email when new articles are posted on . Guidelines for the management of early-stage non-small cell lung cancer were last published in 2013. The new ...

HER2-mutated non-small-cell lung cancer (NSCLC) is a rare form of lung cancer where the cancer cells have a mutation that makes them grow and divide in an uncontrolled way. You can best understand ...

Summit Therapeutics Inc. (NASDAQ:SMMT) is one of the best cancer stocks to invest in now. On February 23, Summit Therapeutics ...